Andrew D. Goldberg is Director of Tarsus Pharmaceuticals, Inc.. Currently has a direct ownership of 6,350 shares of TARS, which is worth approximately $282,511. The most recent transaction as insider was on Jun 24, 2024, when has been sold 3,350 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 6.35K
0% 3M change
217.5% 12M change
Total Value Held $282,511

Andrew D. Goldberg Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 24 2024
BUY
Exercise of conversion of derivative security
-
3,350 Added 34.54%
6,350 Common Stock
Dec 15 2023
BUY
Open market or private purchase
$18,960 $18.96 p/Share
1,000 Added 25.0%
3,000 Common Stock
Jun 16 2023
BUY
Exercise of conversion of derivative security
-
2,000 Added 50.0%
2,000 Common Stock
ADG

Andrew D. Goldberg

Director
Irvine, CA

Track Institutional and Insider Activities on TARS

Follow Tarsus Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TARS shares.

Notify only if

Insider Trading

Get notified when an Tarsus Pharmaceuticals, Inc. insider buys or sells TARS shares.

Notify only if

News

Receive news related to Tarsus Pharmaceuticals, Inc.

Track Activities on TARS